David J Campbell
Overview
Explore the profile of David J Campbell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
124
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Campbell D, Pandey R, Bloudek L, Carlson J, Wallick C, Veenstra D, et al.
J Manag Care Spec Pharm
. 2024 Aug;
30(9):1013-1024.
PMID: 39213143
Background: The impacts of disease and treatment on a patient's family members and informal caregivers are known as "family spillover effects." Although many formal value frameworks call for the consideration...
2.
Odegard J, Flynn P, Campbell D, Robbins S, Dong L, Wang K, et al.
Vaccine
. 2015 Nov;
34(1):101-9.
PMID: 26571309
Background/objectives: There is currently no licensed prophylactic or therapeutic vaccine for HSV-2 infection. Methods: We developed a novel preclinical vaccine candidate, G103, consisting of three recombinantly expressed HSV-2 proteins (gD...
3.
Farley D, McCloskey L, Thorne B, Tareen S, Nicolai C, Campbell D, et al.
Mol Ther Methods Clin Dev
. 2015 Jun;
2:15017.
PMID: 26029728
It is a current regulatory requirement to demonstrate absence of detectable replication-competent lentivirus (RCL) in lentiviral vector products prior to use in clinical trials. Immune Design previously described an HIV-1-based...
4.
Odegard J, Kelley-Clarke B, Tareen S, Campbell D, Flynn P, Nicolai C, et al.
J Immunother
. 2015 Feb;
38(2):41-53.
PMID: 25658613
Dendritic cells (DCs) are essential antigen-presenting cells for the initiation of cytotoxic T-cell responses and therefore attractive targets for cancer immunotherapy. We have developed an integration-deficient lentiviral vector termed ID-VP02...
5.
Tareen S, Nicolai C, Campbell D, Flynn P, Slough M, Vin C, et al.
Biores Open Access
. 2014 Jan;
2(6):421-30.
PMID: 24380052
Lentiviral vectors (LVs) are being developed for clinical use in humans for applications including gene therapy and immunotherapy. A safety concern for use of LVs in humans is the generation...
6.
McCord P, Messina J, Campbell D, Grady S
Appl Geogr
. 2012 May;
34:189-204.
PMID: 22581989
Human African trypanosomiasis (HAT) and animal African trypanosomiasis (AAT) are significant health concerns throughout much of sub-Saharan Africa. Funding for tsetse fly control operations has decreased since the 1970s, which...
7.
Kargbo D, Wilhelm R, Campbell D
Environ Sci Technol
. 2010 Jun;
44(15):5679-84.
PMID: 20518558
Tapping the lucrative Marcellus Shale natural gas deposits may have a host of environmental concerns.
8.
Hodkinson C, Simpson E, Beattie J, OConnor J, Campbell D, Strain J, et al.
J Endocrinol
. 2009 Apr;
202(1):55-63.
PMID: 19398496
A reciprocal relationship between the endocrine and immune system has been demonstrated under pathophysiological conditions. However, few studies have assessed the relationship between thyroid hormones and immune function in apparently...
9.
Campbell D, Heaton P, Pritchard D, Strain J, Rawlings J, Hannigan B
J Nutr
. 2006 Jun;
136(7 Suppl):2084S-2086S.
PMID: 16772506
No abstract available.
10.
Campbell D
Front Health Serv Manage
. 2002 Oct;
19(1):3-13.
PMID: 12355631
Disaster preparedness is a fundamental responsibility of all hospitals, but the events of September 11 and the continuing threat of terrorism have redefined what institutions must consider in serving as...